Učitavanje...

Perspectives for the Development of CD38-Specific Heavy Chain Antibodies as Therapeutics for Multiple Myeloma

The NAD(+)-metabolizing ectoenzyme CD38 is an established therapeutic target in multiple myeloma. The CD38-specific monoclonal antibodies daratumumab and isatuximab show promising results in the clinic. Nanobodies correspond to the single variable domains (VHH) derived from heavy chain antibodies th...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Front Immunol
Glavni autori: Bannas, Peter, Koch-Nolte, Friedrich
Format: Artigo
Jezik:Inglês
Izdano: Frontiers Media S.A. 2018
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6232533/
https://ncbi.nlm.nih.gov/pubmed/30459772
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2018.02559
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!